CN108853609A - A kind of rhinitis prevention and treatment nasal cavity medicine controlled release treatment bracket - Google Patents
A kind of rhinitis prevention and treatment nasal cavity medicine controlled release treatment bracket Download PDFInfo
- Publication number
- CN108853609A CN108853609A CN201810800822.6A CN201810800822A CN108853609A CN 108853609 A CN108853609 A CN 108853609A CN 201810800822 A CN201810800822 A CN 201810800822A CN 108853609 A CN108853609 A CN 108853609A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- treatment
- lactide
- medicine controlled
- nasal cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/78—Preparation processes
- C08G63/82—Preparation processes characterised by the catalyst used
- C08G63/823—Preparation processes characterised by the catalyst used for the preparation of polylactones or polylactides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2230/00—Compositions for preparing biodegradable polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of preparation methods of rhinitis prevention and treatment nasal cavity medicine controlled release treatment timbering material, this method is to mix L- lactide, glycolide, ethyl acetate, in the catalyst of new and effective zirconium iso-octoate and 1, ring-opening polymerisation under 4- butanediol initiator, poly- (L- lactide-co-caprolactone) random copolymer of high-purity and high molecular weight is prepared in polymerization at a certain temperature.This method once polymerize, and purifies after polymerization by acetone, can produce after washing and drying, prevents and treats nasal cavity medicine controlled release treatment bracket using injection molding rhinitis, which has the advantages of environmental protection, good mechanical performance, biodegradable.
Description
Technical field
[oool] the present invention relates to a kind of preparation methods of rhinitis prevention and treatment nasal cavity medicine controlled release treatment timbering material.
Background technique
In recent years, the ecological environment in China is constantly changing, and causes body illness rate higher and higher, and especially patients with rhinitis is not
It is disconnected to increase.Clinically the disease with nasal obstruction, runny nose, smell decline etc. for cardinal symptom is mostly rhinitis chronic or allergic rhinitis；
The disease incidence of both diseases is 10% or more according to statistics, and the people of northern area about 20% suffers from the different rhinitis of degree, hair
Sick rate is higher.Rhinitis is clinically subdivided into rhinitis chronic and allergic rhinitis；Rhinitis chronic is nasal membrane and submucosa
Chronic inflammation is clinically broadly divided into：Chronic simple rhinitis, chronic hypertrophic rhinitis, chronic rhinitis sicca etc.；Variability
Rhinitis is after susceptible individual contacts allergen, mainly by immunoglobulin E mediation based on ictal sneeze, runny nose and nasal obstruction
Want the schneiderian membrane allergic inflammation of symptom.
Rhinitis chronic and allergic rhinitis significantly affect patients ' life quality though both diseases are not serious diseases,
Such as nasal obstruction, runny nose, smell decline sense of discomfort, most of patients loss of appetite, easily tired, failure of memory and adjoint insomnia, have
Can also lead to work efficiency drop with headache, dizziness etc., these symptoms, some patientss anxiety, mood are irritated, and some is also drawn
Mental handicape is played, comes many trouble and inconvenience to daily life and work belt.The treatment cycle of rhinitis chronic is long, allergia nose
Scorching recurrent exerbation is both needed to long term frequent medication, and medication effect is unobvious, and some also worries that the secondary of long-term administration makees
With, therefore most of patient does not adhere to that system specifications is treated, the status of annoying symptom and doctor from property difference based on patients with rhinitis, head
The nasal cavity medicine controlled release treatment bracket of wound, is placed in nasal cavity inflammation edematous site, and local administration simultaneously supports nasal obstruction position, reduces patient
Sense of discomfort.The slow release pharmaceutical preparation of installation with hanger substitutes systemic administration, by drug side-effect minimize and can for a long time to
Medicine；And the micromechanics supporting role of bracket, rapid recovery nasal obstruction symptom, smooth breathing is kept, mitigates rhinitis to the greatest extent and suffers from
The symptom of person, the treatment frame do not influence the daily life of patient, while removing the trouble of repetitively administered from yet, are clinical treatment rhinitis
New, the preferable remedy measures of effect.
The most important western medical treatment means of rhinitis are glucocorticoid Topical treatment, operative treatment when serious at present；In
There are the acupoint therapies methods such as Chinese medicine preparation treatment method, stimulation (injection acupuncture, is massaged, sunken cord) fragrant cave in hospital face.From in recent years
Documents and materials summarize, treatment of rhinitis effect most preferably local glucocorticoid, but hormone is larger to body side effect, and long
Phase use can produce drug resistance；Traditional Chinese medicine and the method report of theory of traditional Chinese medical science treatment are more, but Chinese medicine therapeutic effect is bad, also
The disadvantages of it is cumbersome that there are decocting for Chinese herbal medicine, and medication is inconvenient, therefore many patients are reluctant to receive.
Rhinitis be one it is prolonged and repeated breaking-out, when it is light when weight chronic process, treatment cycle is longer, takes excessive drug
Irreversibility can be caused to injure to the immune system of itself, generally be difficult to adhere to treating.And the rhinitis prevention and treatment of this project development
Nasal cavity medicine controlled release treatment bracket can carry out corresponding relatively good prophylactic treatment to patients with rhinitis.Nasal cavity bracket can prop up first
The nasal passage occluded by oedema is supportted, keeps patient respiratory unobstructed, the sense of discomfort of the reduction patient of maximum possible；Secondly by
The slow release of the therapeutic agent of apposition on bracket, can local administration, achieve the purpose that treat rhinitis；And Stent Implantation it is convenient and
Can long term administration, do not influence the daily routine life of patient.Rhinitis prevents and treats the development of nasal cavity medicine controlled release treatment bracket, local administration
The bioavilability of drug is increased, good absorbing works quickly, easy to use and Small side effects；Supporting support props up oedema portion
The sleep quality of patient is improved in position, reduces sense of discomfort, can effectively improve the quality of life of patient.Develop, produce and use nose
Chamber medicine controlled releasing treats bracket, and prophylactic treatment patients with rhinitis reduces its disease incidence, has important clinical meaning.Market at present
On also have relevant timbering material, such as poly- (L- lactide-co-caprolactone) material, but needs when being synthetically prepared
Use stannous octoate as catalyst, the oxidizable decomposition of the catalyst and to human body toxic side effect, entire synthesis and preparation process
Complexity, energy consumption is higher, and product quality is not uniform enough.
Summary of the invention
For above situation, the object of the present invention is to provide the materials that one kind can replace stannous octoate catalyst, and make
The novel preparation method of standby lower poly- (L- lactide-co-caprolactone) timbering material of simple process energy consumption.
Present inventor is had found by deep experiment and research, is mixed using by L- lactide, glycolide, ethyl acetate
It closes, the ring-opening polymerisation under catalyst and 1,4-butanediol the initiator effect of new and effective zirconium iso-octoate gathers at a certain temperature
Poly- (L- lactide-co-caprolactone) random copolymer for preparing high-purity and high molecular weight is closed, which can be using note
Moulding molding method can be obtained environment-friendly high-efficiency, biocompatibility and biodegradable rhinitis medicine controlled releasing bracket.
The new catalyst zirconium iso-octoate is pulverized solid in the present invention, and dosage is the 3- of raw material total weight
5%.
The mass ratio that L- lactide, glycolide, ethyl acetate mix in the present invention is 4 respectively:6:5.
The temperature of reactive polymeric is 150-160 DEG C in the present invention, polymerization time 3-4h.
The amount of the substance of 1,4-butanediol initiator monomer is 0.1% in the present invention, and dosage is raw material total weight
10-12%.
The following are specific embodiments, are described in further detail again to above content of the present invention.But this should not be understood
Range for the above-mentioned theme of the present invention is only limitted to example below.Without departing from the idea case in the present invention described above, according to
The various replacements or change that ordinary skill knowledge and customary means are made, should all be included within the scope of the invention.
Specific embodiment
Embodiment 1
L- lactide 40g, glycolide 60g, ethyl acetate 50g are mixed, urging for the zirconium iso-octoate of 4.5g is added after mixing
Agent, uniform stirring add the 1,4-butanediol initiator 15g that the amount of substance is 0.1% after 30 minutes, then slowly heating
Ring-opening polymerisation at a temperature of to 160 DEG C can prepare high-purity and high score after reaction in 3 hours after acetone and washing and drying
Poly- (L- lactide-co-caprolactone) random copolymer of son amount, the copolymer can be can be obtained using the method for injection molding
Environment-friendly high-efficiency, biocompatibility and biodegradable rhinitis medicine controlled releasing bracket.
Embodiment 2
L- lactide 100g, glycolide 150g, ethyl acetate 125g are mixed, the zirconium iso-octoate of 11.25g is added after mixing
Catalyst, uniform stirring add the 1,4-butanediol initiator 40g that the amount of substance is 0.1%, then slowly rise after 30 minutes
Temperature can prepare high-purity and height after reaction in 3 hours to ring-opening polymerisation at a temperature of 150 DEG C after acetone and washing and drying
Poly- (L- lactide-co-caprolactone) random copolymer of molecular weight, the copolymer can be obtained using the method for injection molding
To environment-friendly high-efficiency, biocompatibility and biodegradable rhinitis medicine controlled releasing bracket.
Embodiment 3
L- lactide 1000g, glycolide 1500g, ethyl acetate 1250g are mixed, the isooctyl acid of 130g is added after mixing
Zr catalyst, uniform stirring add the 1,4-butanediol initiator 420g that the amount of substance is 0.1% after 30 minutes, then slowly
Ring-opening polymerisation at a temperature of being warming up to 160 DEG C prepares high-purity and high score after acetone and washing and drying after reaction in 4 hours
Poly- (L- lactide-co-caprolactone) random copolymer of son amount, the copolymer can be can be obtained using the method for injection molding
Environment-friendly high-efficiency, biocompatibility and biodegradable rhinitis medicine controlled releasing bracket.
Claims (5)
1. a kind of preparation method of rhinitis prevention and treatment nasal cavity medicine controlled release treatment timbering material, this method by L- lactide, glycolide,
Ethyl acetate mixing, the ring-opening polymerisation under catalyst and 1,4-butanediol the initiator effect of new and effective zirconium iso-octoate, one
Determine poly- (L- lactide-co-caprolactone) random copolymer that high-purity and high molecular weight are prepared in polymerization at temperature, the copolymer
Environment-friendly high-efficiency, biocompatibility and biodegradable rhinitis medicine controlled releasing branch can be can be obtained using the method for injection molding
Frame.
2. the method as described in claim 1, it is characterized in that the new catalyst zirconium iso-octoate is pulverized solid, dosage is
The 3-5% of raw material total weight.
3. the method as described in claim 1, it is characterized in that the mass ratio point of L- lactide, glycolide, ethyl acetate mixing
It is not 4:6:5.
4. the method as described in claim 1, it is characterized in that the temperature of reactive polymeric is 150-160 DEG C, polymerization time 3-4h.
5. the method as described in claim 1 is used it is characterized in that the amount of the substance of 1,4-butanediol initiator monomer is 0.1%
Amount is the 10-12% of raw material total weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810800822.6A CN108853609A (en) | 2018-07-20 | 2018-07-20 | A kind of rhinitis prevention and treatment nasal cavity medicine controlled release treatment bracket |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810800822.6A CN108853609A (en) | 2018-07-20 | 2018-07-20 | A kind of rhinitis prevention and treatment nasal cavity medicine controlled release treatment bracket |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108853609A true CN108853609A (en) | 2018-11-23 |
Family
ID=64303767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810800822.6A Withdrawn CN108853609A (en) | 2018-07-20 | 2018-07-20 | A kind of rhinitis prevention and treatment nasal cavity medicine controlled release treatment bracket |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108853609A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911983A (en) * | 2006-08-17 | 2007-02-14 | 同济大学 | Preparation method of degradable polymer material for stent in shape memory pipe cavity |
| CN105694007A (en) * | 2016-03-10 | 2016-06-22 | 北京悦康科创医药科技股份有限公司 | Novel preparation method of star PLGA (polylactic-co-glycolic acid) |
-
2018
- 2018-07-20 CN CN201810800822.6A patent/CN108853609A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911983A (en) * | 2006-08-17 | 2007-02-14 | 同济大学 | Preparation method of degradable polymer material for stent in shape memory pipe cavity |
| CN105694007A (en) * | 2016-03-10 | 2016-06-22 | 北京悦康科创医药科技股份有限公司 | Novel preparation method of star PLGA (polylactic-co-glycolic acid) |
Non-Patent Citations (4)
| Title |
|---|
| 刘文: "《全国中医药行业高等教育"十三五"规划教材 药用高分子材料学》", 31 July 2017 * |
| 周超等: "聚乳酸－ 乙醇酸共聚物合成与降解", 《生物骨科材料与临床研究》 * |
| 张春红等: "《高分子材料》", 29 February 2016 * |
| 马聪鹤等: "合成聚(丙交酯-co-ε-己内酯)的催化剂研究进展", 《化学研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109700903A (en) | A kind of sleep sachet and preparation method thereof for insomniac | |
| CN102846955A (en) | Chinese herbal medicine heightening insole | |
| CN108853609A (en) | A kind of rhinitis prevention and treatment nasal cavity medicine controlled release treatment bracket | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN103768275B (en) | A kind of Chinese medicine hair-growing liquid for the treatment of seborrheic alopecia | |
| CN103638131B (en) | The medicine for the treatment of thrush | |
| CN103356939B (en) | Medicine for treatment of enuresis and its preparation method | |
| CN108704079A (en) | A kind of Traditional medicine bubble bath composition, preparation method and application improving cold in children fever symptoms | |
| CN101766778A (en) | Traditional Chinese medicine composite for improving male sexual function and curing sexual disfunction and preparation method thereof | |
| CN102579558B (en) | Application of bauhinia championii total flavonoids in preparation of medicine for treating rheumatoid arthritis | |
| WO2016074117A1 (en) | Pharmaceutical composition for treating deficiency of kidney and preparation method therefor | |
| CN107349310B (en) | Traditional Chinese medicine composition for treating cancer pain and application thereof | |
| CN101474267B (en) | Medicament for treating psychasthenia, insomnia, vexation, encephalatrophy and dementia | |
| CN101129770A (en) | Traditional Chinese medicine for treating chronic constipation | |
| CN102406739B (en) | Traditional Chinese medicine for treating child hernia and preparation method thereof | |
| CN109985115B (en) | Traditional Chinese medicine tea bag for treating constipation | |
| CN102836178A (en) | Externally-applied medicine for treating otitis media | |
| CN101214309B (en) | Medicament for treating chronic colon/rectum mucous membrane inflammation | |
| CN103301510B (en) | Acupuncture implantation material | |
| CN107875224A (en) | A kind of spontaneous heating external application Traditional Chinese medicine used as analgesic composition and preparation method thereof | |
| CN101919799B (en) | Novel sustained-release transdermal medicament delivery system | |
| CN113116905A (en) | A composition for improving male sexual function and continuously improving sexual dysfunction, and its preparation method | |
| CN106309659A (en) | Acupoint plaster for hypertension | |
| CN105055714A (en) | Traditional Chinese medicine and traditional Chinese medicine sleeping pillow for treating insomnia | |
| CN107184836A (en) | Conciousness disorder and the Chinese medicine composition of palpitation with fear caused by one kind treatment " Suo Long " disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181123 |